Cargando…
Rapamycin and trametinib: a rational combination for treatment of NSCLC
Mammalian target of rapamycin (mTOR) is one of the most commonly activated pathways in human cancers, including lung cancer. Targeting mTOR with molecule inhibitors is considered as a useful therapeutic strategy. However, the results obtained from the clinical trials with the inhibitors so far have...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Ivyspring International Publisher
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375233/ https://www.ncbi.nlm.nih.gov/pubmed/34421360 http://dx.doi.org/10.7150/ijbs.62752 |